Skip to main content
Top
Published in: Medical Oncology 2/2013

01-06-2013 | Original Paper

Polymorphic CT dinucleotide repeat in the GATA3 gene and risk of breast cancer in Iranian women

Authors: Aghaabdollahian Zakieh, Hematti Simin, Safari Forousan, Tavassoli Manoochehr

Published in: Medical Oncology | Issue 2/2013

Login to get access

Abstract

GATA3 is an enriched transcription factor in mammary epithelium. To date, there has been no study on the relationship between microsatellites in the GATA3 gene and breast cancer risk. In this study, we investigated the existence of polymorphisms in the cytosine–thymine (CT) dinucleotide repeat in intron 3 of the GATA3 gene and its association with breast cancer risk. A case–control study of 206 breast cancer patients and 262 controls was conducted in Iranian women. Several different CT repeat alleles of GATA3 were detected in both the patients and controls. The frequencies of 17 and 18 alleles in patients were significantly lower than controls. Our findings demonstrate that women who carry 17-CT (OR = 0.5; p = 0.003) or 18-CT (OR = 0.41, p = 0.02) alleles of GATA3 gene are at lower risk of developing breast cancer. The highest protection against breast cancer was observed with heterozygotes of 16/17 repeats (OR = 0.12, p = 0.02). Also, the presence of the 17-CT allele has a positive relation with estrogen receptor expression. However, we found that the allelic length of GATA3 polymorphisms had no significant effect on the age onset or grade of the disease, as well as the expression of progesterone receptors and HER2.
Literature
1.
go back to reference Dumitrescu RG, Cotarla I. Understanding breast cancer risk- where do we stand in 2005. J Cell Mol Med. 2005;9:208–21.PubMedCrossRef Dumitrescu RG, Cotarla I. Understanding breast cancer risk- where do we stand in 2005. J Cell Mol Med. 2005;9:208–21.PubMedCrossRef
2.
go back to reference Alvarez RH. Present and future evolution of advanced breast cancer therapy. Breast Cancer Res. 2010;12(Suppl 2: S1):1–18.CrossRef Alvarez RH. Present and future evolution of advanced breast cancer therapy. Breast Cancer Res. 2010;12(Suppl 2: S1):1–18.CrossRef
3.
go back to reference Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, Ebrahimi M. Breast cancer in Iran: an epidemiological review. Breast J. 2007;13:383–91.PubMedCrossRef Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, Ebrahimi M. Breast cancer in Iran: an epidemiological review. Breast J. 2007;13:383–91.PubMedCrossRef
4.
go back to reference Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsedeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20:556–63.PubMedCrossRef Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsedeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20:556–63.PubMedCrossRef
5.
go back to reference Yavari P, Mosavizadeh M, Sadrol-Hefazi B, Mehrabi Y. Reproductive characteristics and the risk of breast cancer—a case-control study in Iran. Asian Pac J Cancer Prev. 2005;6:370–5.PubMed Yavari P, Mosavizadeh M, Sadrol-Hefazi B, Mehrabi Y. Reproductive characteristics and the risk of breast cancer—a case-control study in Iran. Asian Pac J Cancer Prev. 2005;6:370–5.PubMed
6.
go back to reference Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ. Breast cancer in Iran: result of a multi-center study. Asian Pac J Cancer Prev. 2004;5:24.PubMed Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ. Breast cancer in Iran: result of a multi-center study. Asian Pac J Cancer Prev. 2004;5:24.PubMed
7.
8.
go back to reference Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell. 2006;127:1041–55.PubMedCrossRef Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell. 2006;127:1041–55.PubMedCrossRef
9.
go back to reference Ciocca V, Daskalakis C, Ciocca RM, Ruiz-Orrico A, Palazzo JP. The significance of GATA3 expression in breast cancer: a 10-year follow-up study. Hum Pathol. 2009;40:489–95.PubMedCrossRef Ciocca V, Daskalakis C, Ciocca RM, Ruiz-Orrico A, Palazzo JP. The significance of GATA3 expression in breast cancer: a 10-year follow-up study. Hum Pathol. 2009;40:489–95.PubMedCrossRef
10.
go back to reference Yan W, Cao QJ, Arenas RB, Bentley B, Shao R. GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem. 2010;285:14042–51.PubMedCrossRef Yan W, Cao QJ, Arenas RB, Bentley B, Shao R. GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem. 2010;285:14042–51.PubMedCrossRef
11.
go back to reference Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, Kleer CG. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res. 2005;65:11259–64.PubMedCrossRef Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, Kleer CG. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res. 2005;65:11259–64.PubMedCrossRef
12.
go back to reference Naylor MJ, Qrmandy CJ. Gata-3 and mammary cell fate. Breast Cancer Res. 2007;2007(9):302–3.CrossRef Naylor MJ, Qrmandy CJ. Gata-3 and mammary cell fate. Breast Cancer Res. 2007;2007(9):302–3.CrossRef
13.
go back to reference Wilson BJ, Giguere V. Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. Mol Cancer. 2008;7:49.PubMedCrossRef Wilson BJ, Giguere V. Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. Mol Cancer. 2008;7:49.PubMedCrossRef
14.
go back to reference Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.PubMedCrossRef Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.PubMedCrossRef
15.
go back to reference Bong PN, Zakaria Z, Muhammad R, Abdullah N, Ibrahim N, Emran NA, Hussain Syed NS. Expression and mutational analysis of GATA3 in Malaysian breast carcinomas. Malays J Pathol. 2010;32:117–22.PubMed Bong PN, Zakaria Z, Muhammad R, Abdullah N, Ibrahim N, Emran NA, Hussain Syed NS. Expression and mutational analysis of GATA3 in Malaysian breast carcinomas. Malays J Pathol. 2010;32:117–22.PubMed
16.
go back to reference Voduc D, Cheang M, Nielsen T. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomark Prev. 2008;17:365–73.CrossRef Voduc D, Cheang M, Nielsen T. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomark Prev. 2008;17:365–73.CrossRef
Metadata
Title
Polymorphic CT dinucleotide repeat in the GATA3 gene and risk of breast cancer in Iranian women
Authors
Aghaabdollahian Zakieh
Hematti Simin
Safari Forousan
Tavassoli Manoochehr
Publication date
01-06-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0504-0

Other articles of this Issue 2/2013

Medical Oncology 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.